NR 565 ADVANCED PHARMACOLOGY
QUESTIONS AND CORRECT
ANSWERS (VERIFIED ANSWERS)
PLUS RATIONALES 2026/2027 Q&A |
INSTANT DOWNLOAD PDF
Core Domains
Pharmacokinetics and Pharmacodynamics
Prescriptive Authority and Regulatory Frameworks
Cardiovascular and Renal Pharmacology
Central Nervous System and Psychopharmacology
Endocrine and Metabolic Pharmacology
Antimicrobial and Antiviral Therapy
Pain Management and Anti-inflammatory Pharmacology
Special Populations (Geriatrics, Pediatrics, Pregnancy)
Pharmacogenomics and Personalized Medicine
Legal, Ethical, and Evidence-Based Prescribing
Introduction
This comprehensive examination assesses the advanced practice
nursing student's mastery of core pharmacological principles
essential for safe and effective prescribing. It evaluates foundational
theory, drug mechanisms, pharmacokinetic processes, and the
application of pharmacotherapy through multiple-choice and
scenario-based questions. The exam emphasizes real-world clinical
decision-making, medication safety, regulatory compliance, and
,ethical prescribing across diverse patient populations. Candidates
must demonstrate competency in drug classification, therapeutic
monitoring, adverse effect recognition, and individualized treatment
planning. This assessment prepares advanced practice nurses for
independent and collaborative pharmacologic management while
reinforcing evidence-based prescribing practices.
Section One: Questions 1–100
1. A patient with a history of peptic ulcer disease requires
chronic NSAID therapy. Which medication would be the most
appropriate choice to minimize gastrointestinal toxicity?
A. Ibuprofen
B. Celecoxib
C. Naproxen
D. Ketorolac
B. Celecoxib
RATIONALE: Celecoxib is a COX-2 selective inhibitor, which
reduces inflammation with a significantly lower risk of
gastrointestinal ulceration compared to non-selective NSAIDs by
sparing COX-1 mediated gastric protection.
2. A prescriber is considering a medication for a patient with
renal impairment. Which pharmacokinetic process is most
significantly affected by decreased renal function?
A. Absorption
B. Distribution
C. Metabolism
D. Excretion
, D. Excretion
RATIONALE: Renal impairment directly reduces the glomerular
filtration rate and tubular secretion, impairing the excretion of
drugs and their active metabolites, leading to accumulation and
toxicity.
3. A patient on warfarin therapy is started on amiodarone for
atrial fibrillation. What is the primary concern with this drug
combination?
A. Increased risk of bleeding
B. Decreased anticoagulant effect
C. Increased risk of hepatotoxicity
D. Reduced antiarrhythmic efficacy
A. Increased risk of bleeding
RATIONALE: Amiodarone inhibits the CYP2C9 and CYP1A2
enzymes responsible for warfarin metabolism, leading to increased
INR and a significantly elevated risk of bleeding.
4. A 65-year-old female presents with a urinary tract infection.
Her eGFR is 35 mL/min/1.73 m². Which antibiotic requires dose
adjustment based on this finding?
A. Nitrofurantoin
B. Cephalexin
C. Doxycycline
D. Azithromycin
B. Cephalexin
, RATIONALE: Cephalexin is primarily excreted by the kidneys
and requires dose adjustment in renal impairment. Nitrofurantoin
is contraindicated when eGFR is less than 60 mL/min.
5. A drug has a half-life of 6 hours. Approximately how long
will it take to reach steady-state plasma concentration with a
fixed dosing regimen?
A. 6 hours
B. 12 hours
C. 30 hours
D. 60 hours
C. 30 hours
RATIONALE: It takes approximately 5 half-lives to reach steady
state, so 5 × 6 hours = 30 hours.
6. The therapeutic index of a drug is defined as:
A. The ratio of the minimum effective dose to the maximum
tolerated dose
B. The ratio of the toxic dose to the effective dose for 50% of the
population
C. The difference between peak and trough drug concentrations
D. The ratio of the drug's half-life to its dosing interval
B. The ratio of the toxic dose to the effective dose for 50% of the
population
RATIONALE: The therapeutic index (TI) is the ratio of the
median toxic dose (TD50) to the median effective dose (ED50). A
narrow TI indicates a small margin of safety.
QUESTIONS AND CORRECT
ANSWERS (VERIFIED ANSWERS)
PLUS RATIONALES 2026/2027 Q&A |
INSTANT DOWNLOAD PDF
Core Domains
Pharmacokinetics and Pharmacodynamics
Prescriptive Authority and Regulatory Frameworks
Cardiovascular and Renal Pharmacology
Central Nervous System and Psychopharmacology
Endocrine and Metabolic Pharmacology
Antimicrobial and Antiviral Therapy
Pain Management and Anti-inflammatory Pharmacology
Special Populations (Geriatrics, Pediatrics, Pregnancy)
Pharmacogenomics and Personalized Medicine
Legal, Ethical, and Evidence-Based Prescribing
Introduction
This comprehensive examination assesses the advanced practice
nursing student's mastery of core pharmacological principles
essential for safe and effective prescribing. It evaluates foundational
theory, drug mechanisms, pharmacokinetic processes, and the
application of pharmacotherapy through multiple-choice and
scenario-based questions. The exam emphasizes real-world clinical
decision-making, medication safety, regulatory compliance, and
,ethical prescribing across diverse patient populations. Candidates
must demonstrate competency in drug classification, therapeutic
monitoring, adverse effect recognition, and individualized treatment
planning. This assessment prepares advanced practice nurses for
independent and collaborative pharmacologic management while
reinforcing evidence-based prescribing practices.
Section One: Questions 1–100
1. A patient with a history of peptic ulcer disease requires
chronic NSAID therapy. Which medication would be the most
appropriate choice to minimize gastrointestinal toxicity?
A. Ibuprofen
B. Celecoxib
C. Naproxen
D. Ketorolac
B. Celecoxib
RATIONALE: Celecoxib is a COX-2 selective inhibitor, which
reduces inflammation with a significantly lower risk of
gastrointestinal ulceration compared to non-selective NSAIDs by
sparing COX-1 mediated gastric protection.
2. A prescriber is considering a medication for a patient with
renal impairment. Which pharmacokinetic process is most
significantly affected by decreased renal function?
A. Absorption
B. Distribution
C. Metabolism
D. Excretion
, D. Excretion
RATIONALE: Renal impairment directly reduces the glomerular
filtration rate and tubular secretion, impairing the excretion of
drugs and their active metabolites, leading to accumulation and
toxicity.
3. A patient on warfarin therapy is started on amiodarone for
atrial fibrillation. What is the primary concern with this drug
combination?
A. Increased risk of bleeding
B. Decreased anticoagulant effect
C. Increased risk of hepatotoxicity
D. Reduced antiarrhythmic efficacy
A. Increased risk of bleeding
RATIONALE: Amiodarone inhibits the CYP2C9 and CYP1A2
enzymes responsible for warfarin metabolism, leading to increased
INR and a significantly elevated risk of bleeding.
4. A 65-year-old female presents with a urinary tract infection.
Her eGFR is 35 mL/min/1.73 m². Which antibiotic requires dose
adjustment based on this finding?
A. Nitrofurantoin
B. Cephalexin
C. Doxycycline
D. Azithromycin
B. Cephalexin
, RATIONALE: Cephalexin is primarily excreted by the kidneys
and requires dose adjustment in renal impairment. Nitrofurantoin
is contraindicated when eGFR is less than 60 mL/min.
5. A drug has a half-life of 6 hours. Approximately how long
will it take to reach steady-state plasma concentration with a
fixed dosing regimen?
A. 6 hours
B. 12 hours
C. 30 hours
D. 60 hours
C. 30 hours
RATIONALE: It takes approximately 5 half-lives to reach steady
state, so 5 × 6 hours = 30 hours.
6. The therapeutic index of a drug is defined as:
A. The ratio of the minimum effective dose to the maximum
tolerated dose
B. The ratio of the toxic dose to the effective dose for 50% of the
population
C. The difference between peak and trough drug concentrations
D. The ratio of the drug's half-life to its dosing interval
B. The ratio of the toxic dose to the effective dose for 50% of the
population
RATIONALE: The therapeutic index (TI) is the ratio of the
median toxic dose (TD50) to the median effective dose (ED50). A
narrow TI indicates a small margin of safety.
